REXULTI Trademark

Trademark Overview


On Thursday, December 14, 2017, a trademark application was filed for REXULTI with the United States Patent and Trademark Office. The USPTO has given the REXULTI trademark a serial number of 79229625. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, September 19, 2025. This trademark is owned by Otsuka Pharmaceutical Co., Ltd.. The REXULTI trademark is filed in the Medical Instrument Products category with the following description:

Medical apparatus and instruments for use in diagnosing and monitoring vital signs of patients with psychiatric and neurological disorders and diseases, dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; Injection devices for medical purposes; syringes and needles for injections and medical purposes; Apparatus and instruments for diagnostic purposes, namely, integrated medical systems comprising m...
rexulti

General Information


Serial Number79229625
Word MarkREXULTI
Filing DateThursday, December 14, 2017
Status709 - CANCELLED - SECTION 71
Status DateFriday, September 19, 2025
Registration Number5688217
Registration DateTuesday, March 5, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 18, 2018

Trademark Statements


Goods and ServicesMedical apparatus and instruments for use in diagnosing and monitoring vital signs of patients with psychiatric and neurological disorders and diseases, dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; Injection devices for medical purposes; syringes and needles for injections and medical purposes; Apparatus and instruments for diagnostic purposes, namely, integrated medical systems comprising medical diagnostic imaging apparatus and software sold as a unit therewith for managing, measuring, monitoring, assessing, controlling, collecting, storing, and examining patient and client data and information captured by the medical system in web-based physical, psychological and neurological examinations conducted at a distance and at a clinic; Medical apparatus and units for dosage, measuring and monitoring, namely, drug delivery devices and systems

Classification Information


International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, September 19, 2025
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameOtsuka Pharmaceutical Co., Ltd.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressTokyo 101-8535
JP

Party NameOtsuka Pharmaceutical Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTokyo 101-8535
JP

Party NameOtsuka Pharmaceutical Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTokyo 101-8535
JP

Trademark Events


Event DateEvent Description
Tuesday, April 10, 2018ASSIGNED TO EXAMINER
Thursday, April 5, 2018SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, April 9, 2018LIMITATION FROM ORIGINAL APPLICATION ENTERED
Tuesday, April 10, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, April 14, 2018APPLICATION FILING RECEIPT MAILED
Tuesday, April 17, 2018NON-FINAL ACTION WRITTEN
Saturday, May 12, 2018REFUSAL PROCESSED BY IB
Monday, October 8, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 18, 2018NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, April 23, 2018REFUSAL PROCESSED BY MPU
Monday, April 23, 2018NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, October 17, 2018ASSIGNED TO LIE
Wednesday, November 28, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, November 28, 2018NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, November 28, 2018NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, December 18, 2018PUBLISHED FOR OPPOSITION
Tuesday, December 18, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 5, 2019REGISTERED-PRINCIPAL REGISTER
Wednesday, June 5, 2019FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, June 26, 2019FINAL DISPOSITION PROCESSED
Wednesday, June 26, 2019FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, March 5, 2024COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, September 19, 2025CANCELLED SECTION 71
Friday, July 12, 2019FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, October 23, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, October 23, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 8, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, December 15, 2018NOTIFICATION PROCESSED BY IB